PM
ACTU

Prosight Management’s Actuate Therapeutics ACTU Stock Holding History

Prosight Management’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-885
Closed -$5.92K – 53
2025
Q3 		$5.92K Buy
+885
New +$6.42K ﹤0.01% 42

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Prosight Management's ACTU Position: Q4 2025 in Review

Prosight Management sold out of Actuate Therapeutics (ACTU) in Q4 2025, closing a stake of 885 shares — an estimated $5.92K sold.

Prosight Management first reported a position in ACTU in Q3 2025 and held it in 1 quarter. The position peaked at $5.92K in Q3 2025. 45 funds tracked by Wall St. Rank hold ACTU as of Q4 2025.

  • Prosight Management reported no remaining Actuate Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Prosight Management sold 885 Actuate Therapeutics shares in Q4 2025, an estimated $5.92K.
  • Prosight Management first reported a position in Actuate Therapeutics in Q3 2025 and held it in 1 quarter.
  • Prosight Management's Actuate Therapeutics position peaked at $5.92K in Q3 2025.
  • 45 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q4 2025.

Based on Prosight Management's 13F filing for Q4 2025, filed 13 Feb 2026.